Emergent Biosolutions Price to Free Cash Flow Ratio 2007-2021 | EBS

Historical price to free cash flow ratio values for Emergent Biosolutions (EBS) since 2007. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emergent Biosolutions Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-21 46.97 104.15
2021-09-30 50.07 $0.45 111.02
2021-06-30 62.99 $2.24 28.07
2021-03-31 92.91 $5.76 16.13
2020-12-31 89.60 $7.34 12.20
2020-09-30 103.33 $5.06 20.40
2020-06-30 79.08 $3.64 21.72
2020-03-31 57.86 $0.95 61.12
2019-12-31 53.95 $1.93 27.96
2019-09-30 52.28 $-3.34 0.00
2019-06-30 48.31 $-0.10 0.00
2019-03-31 50.52 $1.34 37.59
2018-12-31 59.28 $-0.54 0.00
2018-09-30 65.83 $4.38 15.01
2018-06-30 50.49 $1.94 25.98
2018-03-31 52.65 $2.36 22.27
2017-12-31 46.47 $3.05 15.25
2017-09-30 40.45 $1.09 37.20
2017-06-30 33.91 $0.86 39.52
2017-03-31 29.04 $-0.50 0.00
2016-12-31 32.84 $-0.44 0.00
2016-09-30 31.53 $0.01 2694.87
2016-06-30 26.35 $1.73 15.26
2016-03-31 34.06 $2.42 14.06
2015-12-31 37.49 $-0.05 0.00
2015-09-30 26.70 $0.96 27.82
2015-06-30 30.88 $0.76 40.81
2015-03-31 26.95 $0.73 37.15
2014-12-31 25.52 $1.78 14.31
2014-09-30 19.97 $1.02 19.49
2014-06-30 21.05 $0.38 54.82
2014-03-31 23.68 $0.92 25.76
2013-12-31 21.54 $1.50 14.41
2013-09-30 17.85 $0.04 446.26
2013-06-30 13.51 $-0.04 0.00
2013-03-31 13.10 $-0.50 0.00
2012-12-31 15.03 $-0.07 0.00
2012-09-30 13.32 $1.81 7.36
2012-06-30 14.20 $0.46 30.81
2012-03-31 14.99 $-0.18 0.00
2011-12-31 15.78 $-1.16 0.00
2011-09-30 14.46 $-1.19 0.00
2011-06-30 21.13 $0.68 31.11
2011-03-31 22.64 $1.05 21.48
2010-12-31 21.98 $2.33 9.42
2010-09-30 16.17 $0.55 29.37
2010-06-30 15.31 $-0.08 0.00
2010-03-31 15.73 $1.24 12.64
2009-12-31 12.73 $-0.11 0.00
2009-09-30 16.55 $0.72 23.12
2009-06-30 13.43 $0.36 36.84
2009-03-31 12.66 $-1.00 0.00
2008-12-31 24.47 $-0.44 0.00
2008-09-30 12.27 $2.48 4.94
2008-06-30 9.30 $1.38 6.75
2008-03-31 8.36 $0.05 177.46
2007-12-31 4.74 $0.39 12.25
2007-09-30 8.32 $-3.85 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.503B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00